Expression of Genes Relating Hypertension and Efficacy of 4-7-8 Breathing Control on Reducing Blood Pressure

NCT ID: NCT07018128

Last Updated: 2025-12-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-10-01

Study Completion Date

2026-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study consists of two sub-studies. Study 1 investigates gene expression related to the development of hypertension in Thailand, and Study 2 examines the effectiveness of the 4-7-8 breathing technique in reducing blood pressure in individuals with hypertension.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In Study 1, the sample group includes 200 individuals aged 18-59 years, originating from various regions of Thailand but currently residing in the eastern region. Participants may have normal blood pressure, high blood pressure, or have been diagnosed with hypertension. Blood samples from the participants will be analyzed for the following variables: 1) expression of five genes-adrenomedullin (ADM), angiopoietin-like 4 (ANGPTL4), proto-oncogene c-Fos (FOS), prostaglandin-endoperoxide synthase 2 (PTGS2), and ubiquitin specific peptidase 8 (USP8), and 2) markers of inflammation-tumor necrosis factor-alpha and interferon-gamma levels in the blood.

In Study 2, the sample group includes 75 volunteers from Study 1 who are interested in participating. These volunteers will be randomly assigned into three groups of 25 people each. The first group is a control group whose participants will not receive any breathing training. The second group will practice the 4-7-8 breathing technique, which involves inhaling for 4 seconds, holding the breath for 7 seconds, and exhaling for 8 seconds-this constitutes one cycle. They will repeat this for 6 cycles per set, three sets per day, with normal breathing between sets. The third group will practice deep diaphragmatic breathing at a rate of 6-10 breaths per minute for 15 minutes, twice a day. Participants in both the second and third groups are required to follow their assigned breathing programs daily for three consecutive months. At the end of the three months, all participants will be assessed on the same variables measured before the intervention: 1) systolic and diastolic blood pressure levels, 2) blood pressure variability, and 3) inflammation markers, specifically tumor necrosis factor-alpha and interferon-gamma levels in the blood.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Genetic Predisposition to Disease Breathing, Mouth

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Gene Blood pressure Breathing

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Study 1 is a cross-sectional study model and study 2 is an experimental study model.
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Outcome Assessors
Other than investigators, data collectors, and outcome adjudicators, different researchers were assigned as outcomes assessors and data analysts.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study 2: control group

Participants will not receive any breathing training.

Group Type NO_INTERVENTION

No interventions assigned to this group

Study 2: deep breathing

Participants will practice deep diaphragmatic breathing at a rate of 6-10 breaths per minute for 15 minutes, twice a day. Participants are required to follow their assigned breathing programs daily for three consecutive months.

Group Type ACTIVE_COMPARATOR

Study 2: deep breathing

Intervention Type OTHER

Participants in the deep breathing group will be randomized to receive a diaphragmatic deep breathing program. They will be instructed to practice deep breathing at a rate of 6-10 breaths per minute for 15 minutes, twice daily, every day for a duration of 3 months.

Study 2: 4-7-8 breathing

Participants will practice the 4-7-8 breathing technique, which involves inhaling for 4 seconds, holding the breath for 7 seconds, and exhaling for 8 seconds-this constitutes one cycle. They will repeat this for 6 cycles per set, three sets per day, with normal breathing between sets. Participants are required to follow their assigned breathing programs daily for three consecutive months.

Group Type EXPERIMENTAL

Study 2: 4-7-8 breathing

Intervention Type OTHER

Participants in the 4-7-8 breathing group will be randomized to receive a 4-7-8 breathing program. They will follow the 4-7-8 breathing training program, which involves inhaling for 4 seconds, holding the breath for 7 seconds, and exhaling for 8 seconds, counted as one cycle. This pattern is to be repeated for 6 cycles to complete one set. They will perform 12 sets per day-6 sets in the morning and 6 sets in the evening-with normal breathing between each set. This routine will be carried out daily for a duration of 3 months.

Study 2: slow breathing with device

Participants will practice deep breathing using a resistance-based breathing device called "BreathMax" which provides water pressure resistance set at 25% of their maximum inspiratory capacity. The breathing rate will be set at 6 breaths per minute, continued for 15 minutes per session, twice daily. Participants are required to follow their assigned breathing programs daily for three consecutive months.

Group Type ACTIVE_COMPARATOR

Study 2: slow breathing with device

Intervention Type OTHER

Participants in the slow breathing with device group will be randomized to receive a slow breathing with device. They will undergo deep breathing training using a resistance-based breathing device called BreathMax, set at 25% of their maximal inspiratory pressure. The breathing rate will be 6 breaths per minute, continuously for 15 minutes, twice a day. This routine will be performed daily for a duration of 3 months.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Study 2: deep breathing

Participants in the deep breathing group will be randomized to receive a diaphragmatic deep breathing program. They will be instructed to practice deep breathing at a rate of 6-10 breaths per minute for 15 minutes, twice daily, every day for a duration of 3 months.

Intervention Type OTHER

Study 2: 4-7-8 breathing

Participants in the 4-7-8 breathing group will be randomized to receive a 4-7-8 breathing program. They will follow the 4-7-8 breathing training program, which involves inhaling for 4 seconds, holding the breath for 7 seconds, and exhaling for 8 seconds, counted as one cycle. This pattern is to be repeated for 6 cycles to complete one set. They will perform 12 sets per day-6 sets in the morning and 6 sets in the evening-with normal breathing between each set. This routine will be carried out daily for a duration of 3 months.

Intervention Type OTHER

Study 2: slow breathing with device

Participants in the slow breathing with device group will be randomized to receive a slow breathing with device. They will undergo deep breathing training using a resistance-based breathing device called BreathMax, set at 25% of their maximal inspiratory pressure. The breathing rate will be 6 breaths per minute, continuously for 15 minutes, twice a day. This routine will be performed daily for a duration of 3 months.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female
* Aged between 18-59 years
* Of Thai ethnicity
* Diagnosed with hypertension, defined as having an SBP of 140 mmHg or higher, or a DBP of 90 mmHg or higher, or having previously been diagnosed with hypertension and currently taking antihypertensive medication
* Originally from various regions of Thailand and currently residing in the eastern region


* Male or female
* Aged between 18-59 years
* Of Thai ethnicity
* Does not have hypertension, defined as having an SBP below 130 mmHg and a DBP below 85 mmHg, with no prior diagnosis of hypertension and no history of taking antihypertensive medication
* Originally from various regions of Thailand and currently residing in the eastern region


* Male or female, aged 35-59 years
* Diagnosed with hypertension, with blood pressure levels above the normal range, defined as SBP of 130 mmHg or higher, or DBP of 85 mmHg or higher, and currently taking medication
* Originally from various regions of Thailand and currently residing in the eastern region
* Able to communicate effectively

Exclusion Criteria

* Has heart disease, such as valvular stenosis or regurgitation, coronary artery disease, or heart failure
* Has obesity, defined as having a body mass index (BMI) of 30 kg/m² or higher
* Has a fever or is currently experiencing an infectious disease, such as COVID-19, the flu, or other infections
2. Group of individuals with normal blood pressure


* Has heart disease, such as valvular stenosis or regurgitation, coronary artery disease, or heart failure
* Has obesity, defined as having a body mass index (BMI) of 30 kg/m² or higher
* Has a fever or is currently experiencing an infectious disease, such as COVID-19, the flu, or other infections

Study 2:


* Has respiratory diseases, cardiovascular diseases, cerebrovascular disease, kidney disease, cancer, or immune-related conditions such as allergies, autoimmune diseases (e.g., SLE), immunodeficiency, or rheumatoid arthritis
* Is obese, defined as having a body mass index (BMI) of 30 kg/m² or higher
* Has a fever or is currently infected, such as with COVID-19, the flu, or other infectious diseases
* Is currently pregnant, breastfeeding, or has a history of pregnancy within the 6 months prior to participating in the study
Minimum Eligible Age

18 Years

Maximum Eligible Age

59 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Burapha University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Piyapong Prasertsri

Associate Professor Dr.

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Faculty of Allied Health Sciences, Burapha University

MueangChonburi, Changwat Chon Buri, Thailand

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Thailand

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Piyapong Prasertsri, Ph.D.

Role: CONTACT

Phone: 6638103166

Email: [email protected]

Tadsawiya Padkao, Ph.D.

Role: CONTACT

Phone: 6638103166

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Piyapong Prasertsri, Ph.D.

Role: primary

Tadsawiya Padkao, Ph.D.

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB1-046/2568

Identifier Type: -

Identifier Source: org_study_id